Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas.
Breast cancer
Histologic subtype
Intrinsic subtype
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
15
08
2018
accepted:
06
12
2018
pubmed:
9
1
2019
medline:
5
3
2019
entrez:
9
1
2019
Statut:
ppublish
Résumé
The dominant invasive breast cancer histologic subtype, ductal carcinoma, shows intrinsic subtype diversity. However, lobular breast cancers are predominantly Luminal A. Both histologic subtypes show distinct relationships with patient and tumor characteristics, but it is unclear if these associations remain after accounting for intrinsic subtype. Generalized linear models were used to estimate relative frequency differences (RFDs) and 95% confidence intervals (95% CIs) for the associations between age, race, tumor characteristics, immunohistochemistry (IHC) and RNA-based intrinsic subtype, TP53 status, and histologic subtype in the Carolina Breast Cancer Study (CBCS, n = 3,182) and The Cancer Genome Atlas (TCGA, n = 808). Relative to ductal tumors, lobular tumors were significantly more likely to be Luminal A [CBCS RNA RFD: 44.9%, 95% CI (39.6, 50.1); TCGA: RFD: 50.5%, 95% CI (43.9, 57.1)], were less frequent among young (≤ 50 years) and black women, were larger in size, low grade, less frequently had TP53 pathway defects, and were diagnosed at later stages. These associations persisted among Luminal A tumors (n = 242). While histology is strongly associated with molecular characteristics, histologic associations with age, race, size, grade, and stage persisted after restricting to Luminal A subtype. Histology may continue to be clinically relevant among Luminal A breast cancers.
Sections du résumé
BACKGROUND
BACKGROUND
The dominant invasive breast cancer histologic subtype, ductal carcinoma, shows intrinsic subtype diversity. However, lobular breast cancers are predominantly Luminal A. Both histologic subtypes show distinct relationships with patient and tumor characteristics, but it is unclear if these associations remain after accounting for intrinsic subtype.
METHODS
METHODS
Generalized linear models were used to estimate relative frequency differences (RFDs) and 95% confidence intervals (95% CIs) for the associations between age, race, tumor characteristics, immunohistochemistry (IHC) and RNA-based intrinsic subtype, TP53 status, and histologic subtype in the Carolina Breast Cancer Study (CBCS, n = 3,182) and The Cancer Genome Atlas (TCGA, n = 808).
RESULTS
RESULTS
Relative to ductal tumors, lobular tumors were significantly more likely to be Luminal A [CBCS RNA RFD: 44.9%, 95% CI (39.6, 50.1); TCGA: RFD: 50.5%, 95% CI (43.9, 57.1)], were less frequent among young (≤ 50 years) and black women, were larger in size, low grade, less frequently had TP53 pathway defects, and were diagnosed at later stages. These associations persisted among Luminal A tumors (n = 242).
CONCLUSIONS
CONCLUSIONS
While histology is strongly associated with molecular characteristics, histologic associations with age, race, size, grade, and stage persisted after restricting to Luminal A subtype. Histology may continue to be clinically relevant among Luminal A breast cancers.
Identifiants
pubmed: 30617775
doi: 10.1007/s10552-018-1121-1
pii: 10.1007/s10552-018-1121-1
pmc: PMC6396692
mid: NIHMS1005780
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
31-39Subventions
Organisme : NCI NIH HHS
ID : U01 CA179715
Pays : United States
Organisme : National Institutes of Health
ID : R01 CA19575401
Organisme : NCI NIH HHS
ID : U54 CA156733
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES010126
Pays : United States
Organisme : Susan G. Komen
ID : CCR16376756
Pays : United States
Organisme : National Institutes of Health
ID : U54 CA156733
Organisme : National Institutes of Health
ID : R01 HG009125
Organisme : National Institutes of Health
ID : P30 ES010126
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG009125
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA195740
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA142538
Pays : United States
Organisme : National Institutes of Health
ID : P50 CA058223
Organisme : National Institutes of Health
ID : U01 CA179715
Organisme : National Institutes of Health
ID : P01 CA142538
Références
J Natl Med Assoc. 2001 Sep;93(9):329-34
pubmed: 11560288
Breast Cancer Res Treat. 2001 Jul;68(1):33-43
pubmed: 11678307
Breast Cancer Res. 2004;6(3):R149-56
pubmed: 15084238
J Clin Oncol. 2005 Jan 1;23(1):41-8
pubmed: 15625359
Am J Epidemiol. 2005 Aug 1;162(3):199-200
pubmed: 15987728
Br J Cancer. 2005 Oct 31;93(9):1046-52
pubmed: 16175185
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
BMC Cancer. 2006 Dec 06;6:276
pubmed: 17150101
Breast Cancer Res Treat. 2008 Sep;111(1):121-7
pubmed: 17929165
Breast Cancer Res Treat. 2009 Mar;114(2):243-50
pubmed: 18404368
J Clin Oncol. 2008 Jun 20;26(18):3006-14
pubmed: 18458044
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Am J Surg. 2009 Oct;198(4):516-9
pubmed: 19800459
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1643-54
pubmed: 20501751
World J Surg Oncol. 2010 Jun 21;8:51
pubmed: 20565965
BMC Cancer. 2010 Dec 03;10:664
pubmed: 21126378
Clin Cancer Res. 2010 Dec 15;16(24):6100-10
pubmed: 21169259
Horm Cancer. 2010 Jun;1(3):156-65
pubmed: 21761358
Breast Cancer Res Treat. 2012 Jun;133(2):713-23
pubmed: 22399188
World J Surg Oncol. 2012 Jul 17;10:152
pubmed: 22805492
Breast Cancer Res Treat. 2012 Aug;135(1):271-80
pubmed: 22810087
Breast Cancer Res Treat. 2012 Nov;136(1):35-43
pubmed: 22961065
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Cancer Res Clin Oncol. 2013 Apr;139(4):617-23
pubmed: 23269487
Br J Cancer. 2013 Feb 5;108(2):285-91
pubmed: 23299541
Eur J Surg Oncol. 2013 May;39(5):455-60
pubmed: 23490334
Breast Cancer Res Treat. 2013 Apr;138(3):719-26
pubmed: 23535842
Breast Cancer. 2015 Jul;22(4):374-81
pubmed: 23925582
Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):7-21
pubmed: 23959112
World J Surg Oncol. 2014 Mar 13;12:56
pubmed: 24621330
Ann Surg Oncol. 2014 Dec;21(13):4152-8
pubmed: 24980090
Int J Clin Exp Pathol. 2014 May 15;7(6):3389-98
pubmed: 25031766
Histopathology. 2015 Feb;66(3):409-19
pubmed: 25283075
Womens Health (Lond). 2014 Sep;10(5):511-8
pubmed: 25335542
Breast Cancer Res Treat. 2015 Jan;149(2):555-64
pubmed: 25604797
Ann Surg Oncol. 2015 Aug;22(8):2475-82
pubmed: 25805233
Yonsei Med J. 2015 May;56(3):598-607
pubmed: 25837163
JAMA Surg. 2015 Aug;150(8):815-6
pubmed: 26061977
Breast J. 2015 Sep-Oct;21(5):533-7
pubmed: 26190560
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):398-404
pubmed: 26200835
J Clin Oncol. 2015 Sep 1;33(25):2772-9
pubmed: 26215945
AJR Am J Roentgenol. 2015 Sep;205(3):W374-81
pubmed: 26295674
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Contemp Oncol (Pozn). 2015;19(3):220-5
pubmed: 26557763
Int J Cancer. 2016 May 15;138(10):2346-56
pubmed: 26684063
Clin Radiol. 2016 Feb;71(2):159-63
pubmed: 26703116
Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):470-8
pubmed: 26711328
Clin Med Insights Pathol. 2015 Dec 21;8:23-31
pubmed: 26740749
NPJ Breast Cancer. 2018 Jun 25;4:13
pubmed: 29951581
Breast Cancer Res Treat. 1995 Jul;35(1):51-60
pubmed: 7612904